Airway Therapeutics Announces FDA Acceptance of IND for AT-100's Second Indication in Severe COVID-19 Patients
PR88944
CINCINNATI, Apr. 12, 2021 /PRNewswire=KYODO JBN/ --
-- Initiating Phase 1b clinical trial with initial results expected 3Q2021
-- Potential for novel therapeutic AT-100 to inhibit viral replication, promote
viral elimination and reduction of lung injury, inflammation, and secondary
infections in severe COVID-19 patients
Airway Therapeutics (
), Inc., a biopharmaceutical company developing a new class of biologics to
break the cycle of injury and inflammation for patients with respiratory and
inflammatory diseases, today announced the U.S. Food and Drug Administration
(FDA) has accepted its Investigational New Drug (IND) application to develop
AT-100 (rhSP-D) as a treatment for COVID-19. Airway is leveraging the FDA's
Coronavirus Treatment Acceleration Program (CTAP) that is aimed at evaluating
new treatment options for COVID-19.
Logo - https://mma.prnewswire.com/media/1122328/Airway_Therapeutics_Logo.jpg
Airway will initiate a Phase 1b clinical trial to confirm the feasibility of
intratracheal administrations of AT-100 and its beneficial safety and
tolerability profile.
Airway's novel human recombinant protein AT-100 – an engineered version of an
endogenous protein – has been shown in preclinical studies to safely reduce
inflammation and infection while modulating the immune response across a range
of respiratory diseases inside and outside the lung. Additionally, preclinical
studies of AT-100 have shown potential to inhibit SARS-CoV-2 replication and
promote viral elimination. AT-100 may also reduce secondary infections in
severe COVID-19 patients who are mechanically ventilated in intensive care.
This multidimensional approach differentiates AT-100 from other COVID-19
treatments in development.
"The pre-clinical data are encouraging and lead us to believe that AT-100 has
therapeutic potential against COVID-19 by reducing infection and inflammation
in mechanically ventilated seriously-ill patients who require a range of
treatment options," said Marc Salzberg, M.D., CEO of Airway. "We are excited to
advance the clinical development of AT-100 with the goal of delivering a novel
therapy for severely ill COVID-19 patients who are in need of new treatment
options."
In March, the FDA approved Airway's first IND application to develop AT-100 as
a preventive treatment for the serious respiratory disease bronchopulmonary
dysplasia (BPD) in very preterm infants. The Phase 1b clinical trial will begin
later this month.
About AT-100
AT-100 is a novel recombinant human protein rhSP-D, an engineered version of an
endogenous protein that reduces inflammation and infection in the body while
modulating the immune response to break the cycle of injury and inflammation.
Airway is focused on advancing AT-100 for the prevention of BPD in very preterm
born babies and as a therapeutic for seriously ill COVID-19 patients. AT-100's
anti-inflammatory and anti-infective properties also make it a potential
treatment for other respiratory diseases such as influenza, respiratory
syncytial virus (RSV) and inflammatory diseases outside the lung. The FDA and
European Medicines Agency have granted AT-100 Orphan Drug Designation.
About Airway Therapeutics
Airway Therapeutics is a biopharmaceutical company developing a new class of
biologics to break the cycle of injury and inflammation for patients with
respiratory and inflammatory diseases, beginning with the most vulnerable
populations. The company is advancing the novel recombinant human protein
rhSP-D, an engineered version of an endogenous protein that reduces
inflammation and infection in the body while modulating the immune response.
AT-100 is Airway's first candidate in development for prevention of BPD in very
preterm infants and for treatment of COVID-19 in seriously ill mechanically
ventilated patients. To learn more, visit: https://www.airwaytherapeutics.com.
SOURCE: Airway Therapeutics, Inc.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。